GlassScriptPhysician profile
Nilufer A Guleyupoglu
NPI 1013998996
$3,476.10
in general payments reported to CMS, 2019-2025
25 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $429 · 2021: $348 · 2022: $417 · 2023: $844 · 2024: $691 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,190.80 | 2020-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $536.37 | 2020-2025 | Xtampza |
| Boston Scientific Corporation | $268.52 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $216.61 | 2020-2022 | |
| Medtronic, INC. | $183.39 | 2023 | Intellis Adaptivestim |
| Allergan, INC. | $177.93 | 2019-2022 | |
| Fidia Pharma USA INC. | $147.01 | 2019-2024 | Hymovis |
| Ibsa Pharma INC. | $138.35 | 2020-2025 | Tirosint, Licart, Tirosint |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.00 | 2025 | Caplyta |
| Abbvie INC. | $56.16 | 2022-2023 | |
| Almatica Pharma LLC | $55.47 | 2023 | Gralise |
| Djo, LLC | $53.42 | 2023 | Cmf |
| Vertex Pharmaceuticals Incorporated | $51.39 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $50.44 | 2024-2025 | Horizant |
| Arbor Pharmaceuticals, INC. | $42.93 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sentynl Therapeutics, INC. | $28.08 | 2019 | |
| Zyla Life Sciences, INC. | $22.28 | 2020 | |
| Vertical Pharmaceuticals, LLC | $18.83 | 2019 | |
| Biodelivery Sciences International, INC. | $18.19 | 2020 | |
| Depuy Synthes Sales INC. | $16.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.68 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.00 | 2019 | |
| Baudax Bio INC. | $14.64 | 2020 | |
| Medline Industries LP | $14.36 | 2023 | |
| Pfizer INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilufer Guleyupoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.